As Biogen takes a preclinical Denali compound targeting amyloid beta forward in Alzheimer’s, Denali is shelving another Alzheimer’s candidate that is partnered with Takeda and hits a different target. Phase I data suggest that the drug, known as TAK-920 or DNL919, has a “narrow therapeutic window” given safety signals, Denali said. Together with Takeda, it now plans to go back to the drawing board, focusing on backup molecules still in the preclinical stage, including potential combinations. Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.
BECOME A PREMIUM SUBSCRIBER